Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Repository of the University of Ljubljana
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Advanced
New in RUL
About RUL
In numbers
Help
Sign in
Details
Defining bath ankylosing spondylitis disease activity index cut-off values for disease activity states in a multinational european cohort of patients with axial spondyloarthritis
ID
Georgiadis, Stylianos
(
Author
),
ID
Rotar, Žiga
(
Author
),
ID
Perdan-Pirkmajer, Katja
(
Author
),
ID
Midtbøll Ørnbjerg, Lykke
(
Author
),
ID
Michelsen, Brigitte
(
Author
),
ID
Perdan-Pirkmajer, Katja
(
Author
)
PDF - Presentation file,
Download
(1,21 MB)
MD5: D03FB1BFBFBE0FDADCF305C6F07498B0
URL - Source URL, Visit
https://pmc.ncbi.nlm.nih.gov/articles/PMC12670041/pdf/ACR2-7-e70125.pdf
Image galllery
Abstract
Objective: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is widely used for assessing disease activity in patients with axial spondyloarthritis (axSpA), particularly in settings where markers of inflammation are unavailable. As no consensus on BASDAI cut-off values exists for disease activity states in axSpA, we aimed to develop and validate such cut-offs against external criteria. Methods: Routine care patients with axSpA initiating a biologic disease-modifying antirheumatic drug in eight European registries were included. Receiver operating characteristic analyses against external criteria were performed to determine optimal BASDAI values for separating remission, low disease activity (LDA), high disease activity (HDA), and very high disease activity (VHDA). Follow-up data at 6 months were used to select BASDAI cut-off values between remission and LDA and between LDA and HDA, whereas baseline data were used to select the cut-off for VHDA. The level of agreement between disease activity states based on BASDAI and Axial Spondyloarthritis Disease Activity Score (ASDAS) cut-off values was assessed using the proportion of discordance and weighted kappa. Results: In this cohort of 4,633 patients, the optimal BASDAI cut-off values between remission, LDA, HDA and VHDA were estimated to be <1.3, <2.5, and >5.3. The proportions of discordance between BASDAI and ASDAS disease activity states were 27.6% (weighted κ = 0.48) in baseline data and 37.6% (weighted κ = 0.28) in 6-month data. Conclusion: BASDAI cut-off values for separating remission, LDA, HDA and VHDA were estimated in >4,600 patients. These cut-off values can be used for assessing disease activity and monitoring patients with axSpA, particularly when laboratory markers are unavailable.
Language:
English
Keywords:
disease activity states
,
ankylosing spondylitis
,
axial spondyloarthritis
,
multinational European cohort
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2025
Number of pages:
11 str.
Numbering:
Vol. 7, iss. 12, art. e70125
PID:
20.500.12556/RUL-177935
UDC:
616-002
ISSN on article:
2578-5745
DOI:
10.1002/acr2.70125
COBISS.SI-ID:
261989635
Publication date in RUL:
15.01.2026
Views:
541
Downloads:
151
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
ACR open rheumatology
Shortened title:
ACR open rheumatol.
Publisher:
Wiley & Sons
ISSN:
2578-5745
COBISS.SI-ID:
529833497
Licences
License:
CC BY-NC 4.0, Creative Commons Attribution-NonCommercial 4.0 International
Link:
http://creativecommons.org/licenses/by-nc/4.0/
Description:
A creative commons license that bans commercial use, but the users don’t have to license their derivative works on the same terms.
Secondary language
Language:
Slovenian
Keywords:
stanja aktivnosti bolezni
,
a nkilozirajoči spondilitis
,
aksialni spondiloartritis
,
multinacionalna evropska kohorta
Projects
Funder:
Novartis Pharma AG
Funder:
UCB Biopharma SRL
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back